These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35075060)

  • 1. Safety and BNT162b2 mRNA COVID-19 vaccination.
    Joob B; Wiwanitkit V
    Acta Biomed; 2022 Jan; 92(6):e2021485. PubMed ID: 35075060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
    Matsumura A; Katsuki K; Akimoto M; Sakuma T; Nakajima Y; Miyazaki T; Fujisawa S; Nakajima H
    Rinsho Ketsueki; 2021; 62(11):1639-1642. PubMed ID: 34866090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-episodic angioedema with eosinophilia after BNT162b2 mRNA COVID-19 vaccination.
    Ishizuka K; Katayama K; Kaji Y; Tawara J; Ohira Y
    QJM; 2021 Dec; 114(10):745-746. PubMed ID: 34546346
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases.
    Fornaro M; Venerito V; Iannone F; Cacciapaglia F
    J Rheumatol; 2022 Mar; 49(3):334-335. PubMed ID: 35033998
    [No Abstract]   [Full Text] [Related]  

  • 5. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.
    Herishanu Y; Avivi I; Levi S; Shefer G; Bronstein Y; Moshiashvili MM; Ziv T; Scarfò L; Perry C; Ghia P
    Blood Adv; 2022 Jan; 6(1):148-151. PubMed ID: 34614513
    [No Abstract]   [Full Text] [Related]  

  • 6. Comment on: Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series.
    Mungmunpuntipantip R; Wiwanitkit V
    Rheumatology (Oxford); 2021 Dec; 61(1):e29. PubMed ID: 34554230
    [No Abstract]   [Full Text] [Related]  

  • 7. Comment on: Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series: reply.
    Furer V; Zisman D; Elkayam O
    Rheumatology (Oxford); 2021 Dec; 61(1):e30. PubMed ID: 34554242
    [No Abstract]   [Full Text] [Related]  

  • 8. Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis.
    Caocci G; Mulas O; Mantovani D; Costa A; Galizia A; Barabino L; Greco M; Murru R; La Nasa G
    Ann Hematol; 2022 Apr; 101(4):929-931. PubMed ID: 34302519
    [No Abstract]   [Full Text] [Related]  

  • 9. Cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine.
    López-Valle A; Falkenhain-López D; Arranz CR
    Int J Dermatol; 2021 Jul; 60(7):891-892. PubMed ID: 33855706
    [No Abstract]   [Full Text] [Related]  

  • 10. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months.
    Ponticelli D; Antonazzo IC; Caci G; Vitale A; Della Ragione G; Romano ML; Borrelli M; Schiavone B; Polosa R; Ferrara P
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34697627
    [No Abstract]   [Full Text] [Related]  

  • 12. BNT162B2 mRNA COVID-19 Vaccine in Heart and Lung Transplanted Young Adults: Is an Alternative SARS-CoV-2 Immune Response Surveillance Needed?
    Cotugno N; Pighi C; Morrocchi E; Ruggiero A; Amodio D; Medri C; Colagrossi L; Russo C; Di Cesare S; Santilli V; Manno EC; Zangari P; Giancotta C; Bernardi S; Nicolosi L; Ciofi Degli Atti M; Raponi M; Zaffina S; Alfieri S; Kirk R; Perno CF; Rossi P; Amodeo A; Palma P
    Transplantation; 2022 Feb; 106(2):e158-e160. PubMed ID: 34954734
    [No Abstract]   [Full Text] [Related]  

  • 13. Eosinophilic cellulitis after BNT162b2 mRNA Covid-19 vaccine.
    de Montjoye L; Marot L; Baeck M
    J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):e26-e28. PubMed ID: 34547138
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients.
    Haller MC; Kaiser RA; Langthaler S; Brandstetter C; Apfalter P; Kerschner H; Cejka D
    Transpl Int; 2021; 35():10026. PubMed ID: 35185359
    [No Abstract]   [Full Text] [Related]  

  • 15. Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine.
    Cyrenne BM; Al-Mohammedi F; DeKoven JG; Alhusayen R
    J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):e546-e548. PubMed ID: 33982814
    [No Abstract]   [Full Text] [Related]  

  • 16. Skin ulcer at the injection site of BNT162b2 mRNA COVID-19 vaccine.
    Aoki N; Saruta Y; Tanaka S; Nakajima R; Sano H; Sano S
    J Dermatol; 2021 Dec; 48(12):e596-e597. PubMed ID: 34545609
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of Graves' Disease After SARS-CoV-2 mRNA Vaccination: A Case Report and Literature Review.
    Lui DTW; Lee KK; Lee CH; Lee ACH; Hung IFN; Tan KCB
    Front Public Health; 2021; 9():778964. PubMed ID: 34888290
    [No Abstract]   [Full Text] [Related]  

  • 18. [Severe thrombocytopenia after COVID-19 mRNA vaccination].
    Hagihara M; Uchida T; Inoue M; Ohara S; Imai Y
    Rinsho Ketsueki; 2021; 62(12):1684-1687. PubMed ID: 35022337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. Reply.
    Walter EB; Talaat KR; Gurtman A
    N Engl J Med; 2022 Feb; 386(6):606. PubMed ID: 35045225
    [No Abstract]   [Full Text] [Related]  

  • 20. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
    Olariu TR; Ursoniu S; Marincu I; Lupu MA
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.